Given the protective effect of the CXCL10 and CXCR3 genetic deletion in our murine dietary model of NASH, pharmacological inhibitions of CXCL10 or CXCR3 are potential therapeutic strategies to attenuate the sterile inflammatory response in human NASH. The gene discussed is CXCR3; the disease is metabolic dysfunction-associated steatohepatitis.